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Edited by Vladimir SkulachevAbstract We have shown previously that calcium could trigger
nuclear fragmentation, which was associated with a caspase 3
(C3)-like activity [Juin, P., Pelletier, M., Oliver, L., Tremblais,
K., Gregoire, M., Meﬂah, K. and Vallette, F.M. (1998) Induc-
tion of a caspase-3-like activity by calcium in normal cytosolic
extracts triggers nuclear apoptosis in a cell-free system. J. Biol.
Chem. 273, 17559]. Here, we report that this activation is asso-
ciated with a non-canonical truncation of C3, which induces a
weak DEVDase activity. The cleavage of C3 via calcium-depen-
dent proteolysis is independent of caspase 9; lysate exposure to
calcium prevents further cleavage and activation by the cyto-
chrome c and dATP pathway. Altogether, our data suggest that
calcium could favour a necrotic mechanism by inducing the gen-
eration of a form of C3 insensitive to mitochondrial activation.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Caspase; Calcium; Apoptosis; Necrosis1. Introduction
Calcium (Ca2+) has been shown to play an essential role in
some major central nervous system (CNS) diseases as it is in-
volved in the degeneration and the death of neurones [1,2].
However, the actual mechanisms implicated in Ca2+-induced
apoptosis appear to be complex and involve several pathways
including the activation of a family of proteases speciﬁcally in-
volved in cell death programmes [1,2]. The relationship be-
tween caspases and Ca2+-activated proteases, such as
calpain, during the execution phase of apoptosis is an ongoing
conundrum, which needs to be solved as considerable eﬀorts
are currently being made to develop highly speciﬁc inhibitors
of calpain and caspase 3 (C3) for therapeutic applications. In
many cases, an increase in the level of free intracellular
[Ca2+] in neurones results in the rapid activation of calpains,
which leads to the degradation of several cytoskeletal and
membrane proteins [1]. This Ca2+-induced cell death, in com-
bination with apoptosis, has been suggested to be involved in
many physio-pathological situations in the CNS [1]. For exam-Abbreviations: C3, caspase 3; pC3, procaspase 3; cyt c, holocytochrome
c; tC3, truncated C3; CNS, central nervous system; Ac-DEVD-AMC,
Ac-Asp-Glu-Val-Asp-AMC
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C3, was responsible for the cell death observed during trauma
and/or ischemia [1]. However, the determination of the precise
molecular pathways of the Ca2+-induced cell death has been
diﬃcult to establish because of the contradictory results pub-
lished on the consequence of calpain-induced caspase cleavage.
For example, the cleavage by calpains has been shown to acti-
vate C3 in a hypoxia/ischemia model and to inhibit its activa-
tion in a Ca2+-channel opener-treated cells [3,4]. Likewise, it
has been reported that calpains could simultaneously inacti-
vate C7 and C9 [5], while other studies have shown that cal-
pains could induce the activation of C7 and C12 [6,7]. In
addition to the cleavage of caspases, calpains have been shown
to cleave several key apoptogenic proteins such as apoptotic
protease activating factor-1 (Apaf-1) and Bax [8], suggesting
that these proteases could also intervene in steps immediately
preceding or following mitochondrial permeabilisation. All
these results suggest that the nature of the induction in the rise
of intracellular [Ca2+] may favour either the activation or the
inactivation of caspases. We have previously reported that
the addition of high concentrations of Ca2+ to a cell extract
was suﬃcient, via the induction of caspase activity, to trigger
nuclear apoptosis in a cell-free assay and this independently
of calpains [9]. We took proﬁt of this simple experimental set
up to study the eﬀect of Ca2+ on the activation of caspases.2. Materials and methods
2.1. Materials
Unless otherwise stated all reagents used in this study were from Sig-
ma (St. Quentin, Fallavier, France). Commercial antibodies raised
against C3 and C9 were from BDPharmingen (559565 and 556585,
respectively). The ﬂuorogenic peptides Ac-Asp-Glu-Val-Asp-AMC
(Ac-DEVD-AMC), a substrate for C3 and Ac-LEHD-AMC a sub-
strate for C9 were obtained from Bachem (Budendorf, Switzerland).
All cell culture material was obtained from Invitrogen (Cergy Pontoise,
France).
2.1.1. Cell culture. The human neuroblastoma cell line SH-SY5Y
was grown in DMEM supplemented with 10% heat-inactivated foetal
calf serum and antibiotics, as described in [10]. The human promyelo-
cytic leukaemia HL60 and HL60/ADR cell lines were grown as de-
scribed previously [11]. Control cellular extracts (CCE) were
obtained from SH-SY5Y, HL60 and HL60/ADR using a protocol sim-
ilar to that described earlier for a rat glioma cell line [9].
2.2. Quantiﬁcation of C3-like activity
CCE (250 lg) was incubated in the presence of the indicated concen-
trations of CaCl2 or cytochrome c (cyt c). In the latter case, dATP
(200 lM) was also added to CCE. The C3 or C9 activity was moni-
tored by measuring the degradation of the ﬂuorometric substrate Ac-
DEVD-AMC or Ac-LEHD-AMC as previously described [9].blished by Elsevier B.V. All rights reserved.
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Immunoblots were performed as described earlier [9]. For the
immunodepletion of C3 or C9, 20 lg antibody was incubated at 4 C
for 24 h with 300 lg CCE. Then 30 ll Protein G–agarose (Sigma)
was added and incubated for a further 24 h at 4 C. The mixture was
then centrifuged 10 min at 10000·g at 4 C and the resulting cytosols
adjusted to 250 lg prior to incubation with Ca2+ and/or cyt c/dATP.
The presence and the processing of C3 and C9 were analysed by immu-
noblots. The depletion of C3 and C9 was veriﬁed in parallel by reprob-
ing the membrane with the appropriate antibody. Note that these
antibodies reacted with both the proenzyme and the active subunit.3. Results
3.1. Comparative induction of DEVDase activity in non-
apoptotic cell extracts by increasing the concentration of
Ca2+ and cyt c
We have previously reported that a C3-like activity mea-
sured by the hydrolysis of the ﬂuorometric peptide Ac-
DEVD-AMC could be generated by the addition of Ca2+ to
non-apoptotic cellular extracts (i.e., CCE) while the addition
of low concentrations of cyt c (i.e., 2 lM) were ineﬀective [9].
We examined the dose-dependent induction of DEVDase
activity using 250 lg CCE prepared from the human neuro-
blastoma cell line SH-SY5Y. As shown in Fig. 1A, a signiﬁcant
increase in DEVDase activity was observed only at Ca2+ con-Fig. 1. Activation of DEVDase activity in CCE. The human neuro-
blastoma cell line, SHSY5Y, was cultivated in 10% FCS in RPMI at
37 C, 5% CO2 for 7 days before the preparation of the CCE
(immunodepleted or not in C3) as described in Section 2. CCE (250 lg)
were incubated for 1 h at 37 C in the presence of increasing
concentration of CaCl2 (from 100 lM to 2 mM) (A) or for 20 min at
37 C in the presence of 200 lM dATP and increasing concentrations
of cyt c (from 5 to 100 lM) (B). At the end of the incubation the
DEVDase activity was measured using the ﬂuorogenic substrate Ac-
DEVD-AMC as described in Section 2. The activity was normalised to
1 for the CCE incubated in the absence of Ca2+ and/or cyt c/dATP.
Data shown are the mean of at least ﬁve independent experiments
(means ± S.D.). \P 6 0.05; \\P 6 0.01.centrations superior to 100 lM (P 6 0.05), peaked at 300 lM
(3-fold increase; P 6 0.00) and decreased at higher concentra-
tions. Note that as described previously [9], the addition of
Ca2+ had no eﬀects on the DEVDase activity measured in cel-
lular extracts obtained from apoptotic cells (data not shown).
On the other hand, the addition of cyt c plus dATP (see Sec-
tion 2), provoked a rapid and important increase in DEVDase
activity at concentrations superior to 10 lM (P 6 0.05) and at-
tained a maximum at 50 lM showing a 30-fold increase (Fig.
1B). However, contrary to what we observed with Ca2+, high
concentrations of cyt c (i.e., P 50 lM) were capable of induc-
ing similar levels of DEVDase activity in these extracts (Fig.
1B). The dose/response induction of DEVDase activity sug-
gested that the pathways involved in Ca2+-induced DEVDase
activity were diﬀerent from those involved in cyt c-induced
DEVDase activity.3.2. Calcium-induced DEVDase activity cannot be further
enhanced by cyt c
We examined the relationships between these two induction
pathways of DEVDase activity by sequential activation of
these activities in CCE derived from the human neuroblastoma
cell line SH-SY5Y. We used concentrations of Ca2+ and cyt c,
which generated the maximal DEVDase activities (i.e., 300 lM
CaCl2 and 50 lM cyt c). Quite spectacularly, pre-treatment of
the CCE with Ca2+ inhibited the cyt c/dATP-induced activa-
tion of Ac-DEVD-AMC as represented in Fig. 2. As illustrated
in Fig. 2, the DEVDase activity was maintained at a level sim-
ilar to that observed with Ca2+ alone. Concurrently, the addi-
tion of 300 lM Ca2+ to a C3-depleted CCE (see Section 2) had
no eﬀect on the induction of DEVDase activity (Fig. 2), show-
ing that this activity was due to C3 (Fig. 2).
Immunoblot analyses of these extracts showed that Ca2+
generated the cleavage of the 32 kDa procaspase 3 (pC3) into
a p25 kDa band (Fig. 2A) which we called truncated C3 (tC3).
At concentrations of Ca2+ superior to 300 lM the tC3 progres-
sively disappeared to be completely degraded at high concen-
tration (i.e., 600 lM) (Fig. 2B). Of note, an important
amount of undegraded p32 C3 was still observed even at high
calcium concentrations (Fig. 2B), which was not activated by
cyt c/dATP (data not shown). When CCE were treated with
cyt c and dATP, two bands of, respectively, 20 and 17 kDa
were observed (Fig. 3A). This data is consistent with previous
results showing the activated forms of C3 detected during
apoptosis [12,13]. In agreement with the DEVDase activities
reported in Fig. 2, the pre-treatment of CCE with Ca2+ prior
to the addition of cyt c/dATP did not result in the appearance
of the p20 and p17 forms of C3 but to that of tC3 (Fig. 3A).
It has been reported that calpain mediated a N-terminal
truncation of C9, which could activate C3 [5,14]. Analysis of
C9 processing in CCE incubated with Ca2+ and/or cyt c/dATP
revealed that both treatments generated the proteolysis of C9
into the mature p37 kDa form (Fig. 3B). In order to determine
the importance of this cleavage in both Ca2+ and cyt c/dATP
activation of C3, CCE were depleted of C9 by immunoprecip-
itation using an anti-C9 antibody (see Section 2). Immunode-
pletion was veriﬁed by immunoblotting of the
immunodepleted CCE with anti-C9 antibodies (data not
shown). C9-immunodepleted CCE was then subjected to
Ca2+ and/or cyt c/dATP treatment before immunoblot analysis
of C3 cleavage. As shown in Fig. 3C, the immunodepletion of
Fig. 2. Eﬀect of Ca2+ pre-treatment on cyt c/dATP induction of
DEVDase activity in CCE. CCE (250 lg) were incubated for 1 h at
37 C in the presence of 300 lM CaCl2 (Ca) or 20 min at 37 C in the
presence of 50 lM cyt c plus 200 lM dATP (cyt c) before determining
the DEVDase activity (A) and immunoblot analysis of the presence of
C3 (B). In some case, CCE were immunodepleted using 5 ll of the
polyclonal antibody directed against human C3 (see Section 2). CCE
were also incubated with CaCl2 prior to the incubation with cyt c/
dATP (Ca/cyt c) or with cyt c/dATP prior to incubation with CaCl2
(cyt c/Ca). The DEVDase activity was quantiﬁed as in Fig. 1.
Fig. 3. CleavageofC3andC9uponCa2+ and/or cyt c/dATP treatments.
Immunoblots were performed as described in Section 2. CCE (250 lg)
were analysed using an antibody directed against C3 (A) or C9 (B) at a
1:1000 dilution. CCE were treated as in Fig. 2 prior to SDS–PAGE and
immunoblot. Immunoblots illustrated are representative of ﬁve inde-
pendent experiments. (C) CCE immunodepleted in C9 still respond to
Ca2+ but not to cyt c/dATP.CCEwere immunodepleted using 5 ll of the
polyclonal antibody directed against human C9 (see Section 2). The
processing of C3 was analysed by immunoblots as in A. Immunoblot
illustrated is representative of ﬁve independent experiments. The
depletion of C9 was veriﬁed in parallel by reprobing the membrane with
the anti-C9 antibody (data not shown).
Fig. 4. The role of Ca2+ in the activation of C3 in HL60 and in HL60/
ADR cells: CCE were prepared form the human leukaemia cell lines as
described in Section 2 and were treated with Ca2+ and/or cyt c then
DEVDase activities and the processing of C3 were performed as in
Figs. 2 and 3. As with SH-SY5Y CCE, Ca2+ (Ca) induced a weak but
signiﬁcant increase in DEVDase activity in HL60 CCE. This was
paralleled by the processing of C3 into tC3 with a molecular weight of
29 kDa, which could not be further activated by the addition of cyt c/
dATP (cyt c). Similar experiments performed with CCE derived from
HL60/ADR showed no activation of C3 by Ca2+ or by cyt c.
Immunoblots showed are representative of at least three independent
experiments. DEVDase activity (means ± S.D.) was calculated from
three diﬀerent experiments.
2366 M. Pelletier et al. / FEBS Letters 579 (2005) 2364–2368C9 did not aﬀect Ca2+-induced C3 cleavage while, as expected,
it prevented that of cyt c/dATP. This result showed that C9
was not involved in the Ca2+-induced DEVDase activity.
These results suggest that Ca2+-induced proteolysis triggered
a direct aberrant processing of tC3, which could not be further
processed into the active C3 subunits (i.e., p20 and p17).
3.3. Mutations in the N-terminus of the p20 subunit of C3
prevent its activation by Ca2+ and by cyt c
We have extended our observation to CCE obtained from
the HL60 cell line. As shown in Fig. 4, upon incubation with
300 lM CaCl2, pC3 was degraded in a tC3 form which corre-
sponds to a p29 kDa cleavage product of C3. This cleavage
was accompanied by a 2-fold increase in DEVDase activity
(P 6 0.05) (Fig. 4). The addition cyt c/dATP induced a 20-fold
increase in the DEVDase activity and the appearance of 2 ma-
jor polypeptides of, respectively, p20 and p17 kDa in the CCE
(Fig. 4), as observed in the CCE of SH-SY5Y.
The incubation of HL60 CCE with Ca2+ prior to the addi-
tion of cyt c inhibited the induction of DEVDase activityand that of the p17 kDa C3 subunit but only partially that
of the p20 kDa form of C3. These results suggest that although
Ca2+ produced a similar activation/inhibition of the DEVDase
activity, the proteolytic processing of the pC3 involved diﬀered
from that observed in SH-SY5Y.
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cell line HL60 resistant to adrianomycin (HL60/ADR) [11].
This mutant, which we called C3-NTM, is modiﬁed in the re-
gion encompassing amino acids 30–36 with the sequence GIS-
LDNS in wild type C3 (i.e., in HL60) and MSWDTG in
C3NTM (i.e., in HL60/ADR). We have shown that these
mutations impair the activation of C3 in HL60/ADR upon
induction of apoptosis [11]. As illustrated in Fig. 4, neither
the addition of cyt c nor that of Ca2+ induced the proteolytic
activation of C3NTM, which suggests that the mutated amino
acids are involved in both activating processes.4. Discussion
The cross-talk between the Ca2+ and the caspase proteolytic
pathways during apoptosis has been extensively studied espe-
cially in the CNS. This cross talk appears to involve many
pathways but it is not known if calcium participates in a con-
tinuum or in a switch between the apoptotic and the necrotic
pathways. Conﬂictual reports have been published on the rela-
tionship between calpain and caspases during cell death prob-
ably due to the multiplicity of cellular targets of these
proteases and the diﬀerent experimental conditions used in
these studies. We have shown that the addition of Ca2+ to cel-
lular extracts at concentration compatible with that observed
during ischemia/reperfusion [15] induced a weak but signiﬁcant
activation of C3. This activation was suﬃcient to trigger cas-
pase-dependent nuclear apoptosis in a cell-free assay [9]. We
have re-evaluated this process in the present study and have
found that this apparent activation leads to the generation of
a form of C3 with a molecular weight of 25 kDa in SH-
SY5Y and 29 kDa in HL60, which we called tC3 for truncated
C3. This diﬀerence in the size of the fragment generated by
Ca2+ in the diﬀerent cell lines suggests the implication of dis-
tinct proteases which are still to be determined. Studies with
the C3NTM allowed us to identify a region, which is involved
in both Ca2+- and cyt c activation of pC3 in HL60. The mech-
anisms by which this sequence regulates both Ca2+ and cyt c
activation of pC3 are still unclear and probably diﬀer from
one cell line to another one. It should be noted, that a large
proportion of pC3 appears to be resistant to cyt c and Ca2+-in-
duced activation (see the proportion of the p32 kDa band
remaining after cyt c or Ca2+ treatments in Figs. 2–4). This
raises the question of a possible action of calcium on other
components of the apoptosome such as apaf-1 as previously
described [16]. Indeed, we observed a degradation of apaf-1
in cell lysates treated with calcium (data not shown) which thus
could make impossible the activation of pC3 not cleaved by
the calcium related process. We also show that the Ca2+-in-
duced C3 activity is independent of the apoptosome as it does
not require the apical C9 as shown by the immunodepletion
experiments (Fig. 3). McGinnis et al. [16] have recently re-
ported that maitotoxin, a potent Ca2+-channel opener, induces
cyt c release from apoptosis in SH-SY5Y which was not fol-
lowed by caspases activation. Consistent with our results,
pC3 appeared under theses conditions to undergo a non-con-
ventional cleavage [16].
Taken together, our results suggest that calpain or another
Ca2+-induced protease can partially activate pC3 in a cellular
extract but this processing precludes the apoptotic activationgenerated by the mitochondria. The amount of caspase re-
quired for the completion of apoptosis diverges from one cell
to another and/or from one apoptotic inducer to another, pre-
sumably because of the presence in the cytosol of XIAPs [17].
Thus, one can postulate that Ca2+ can induce cell death under
conditions, which requires low caspase activity but that it be-
comes an inhibitor when higher C3 activities are necessary.
This feature could be related to a paradoxical role of caspases
in neuroprotection and CNS remodelling [18]. However, the
concentration of Ca2+ necessary to ‘‘activate’’ C3 is more com-
patible with necrosis than apoptosis. One can thus postulate
that under low Ca2+ concentrations, cyt c can activate C3
and that, once a high level of Ca2+ is reached, its activation
by the mitochondrial pathway is inhibited. Interestingly, the
degradation of Apaf-1, another member of the apoptosome
has been shown to be induced by Ca2+-activated proteases
[19]. Taken together, these results suggest that degradation
of Apaf-1 and C3 by Ca2+ prevent cyt c activation of C3 dur-
ing certain types of Ca2+-mediated cell death and also could
explain the mixed apoptotic/necrotic features observed in cer-
tain types of pathological cell death.
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